{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:17:57Z","timestamp":1759342677942},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,10,2]],"date-time":"2012-10-02T00:00:00Z","timestamp":1349136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s10384-012-0182-z","type":"journal-article","created":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T03:46:01Z","timestamp":1349063161000},"page":"536-543","source":"Crossref","is-referenced-by-count":13,"title":["Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy"],"prefix":"10.1007","volume":"56","author":[{"given":"Atsushi","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikatsu","family":"Kaburaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimiko","family":"Okinaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuko","family":"Takamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujiro","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,2]]},"reference":[{"key":"182_CR1","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, Inaba G. Beh\u00e7et\u2019s disease. N Engl J Med. 1999;341:1284\u201391.","journal-title":"N Engl J Med"},{"key":"182_CR2","unstructured":"Beh\u00e7et\u2019s Disease Research Committee of Japan. The revised criteria and manual of treatments of Beh\u00e7et\u2019s Disease (in Japanese). Tokyo: Ministry of Health and Welfare; 2003. p. 11\u201329."},{"key":"182_CR3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/08830189709116844","volume":"14","author":"M Mochizuki","year":"1997","unstructured":"Mochizuki M. Immunotherapy for Beh\u00e7et\u2019s disease. Int Rev Immunol. 1997;14:49\u201366.","journal-title":"Int Rev Immunol"},{"key":"182_CR4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cyto.2003.09.003","volume":"24","author":"M Misumi","year":"2003","unstructured":"Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, et al. Cytokine production profile in patients with Beh\u00e7et\u2019s disease treated with infliximab. Cytokine. 2003;24:210\u20138.","journal-title":"Cytokine"},{"key":"182_CR5","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0140-6736(94)90632-7","volume":"344","author":"MJ Eliott","year":"1994","unstructured":"Eliott MJ, Mani RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor \u03b1 (cA2) in patients with rheumatoid arthritis. Lancet. 1994;344:1125\u20137.","journal-title":"Lancet"},{"key":"182_CR6","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomized trial. Lancet. 2002;359:1541\u20139.","journal-title":"Lancet"},{"key":"182_CR7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0140-6736(07)61129-5","volume":"370","author":"A Menter","year":"2007","unstructured":"Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370:272\u201384.","journal-title":"Lancet"},{"key":"182_CR8","first-page":"672","volume":"29","author":"F Heldmann","year":"2011","unstructured":"Heldmann F, Brandt J, van der Horst-Bruinsma IE, Landewe R, Sieper J, Burmester GR, et al. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol. 2011;29:672\u201380.","journal-title":"Clin Exp Rheumatol"},{"key":"182_CR9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.crohns.2011.11.001","volume":"6","author":"W Reinisch","year":"2012","unstructured":"Reinisch W, Van Assche G, Befrits R, Connell W, D\u2019Haens G, Ghosh S, et al. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis. 2012;6:248\u201358.","journal-title":"J Crohns Colitis"},{"key":"182_CR10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","volume":"94","author":"Y Yamada","year":"2010","unstructured":"Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh\u00e7et disease. Br J Ophthalmol. 2010;94:284\u20138.","journal-title":"Br J Ophthalmol"},{"key":"182_CR11","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","volume":"146","author":"KF Tabbara","year":"2008","unstructured":"Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Beh\u00e7et disease. Am J Ophthalmol. 2008;146:845\u201350.","journal-title":"Am J Ophthalmol"},{"key":"182_CR12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10384-006-0424-z","volume":"51","author":"M Takamoto","year":"2007","unstructured":"Takamoto M, Kaburaki T, Numaga J, Fujino Y, Kawashima H. Long-term infliximab treatment for Beh\u00e7et\u2019s disease. Jpn J Ophthalmol. 2007;51:239\u201340.","journal-title":"Jpn J Ophthalmol"},{"key":"182_CR13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00296-008-0606-8","volume":"29","author":"H Al-Rayes","year":"2008","unstructured":"Al-Rayes H, Al-Swailem R, Al-Balawi M, Al-Dohayan N, Al-Zaidi S, Tariq M. Safety and efficacy of infliximab therapy in active Behcet\u2019s uveitis: an open-label trial. Rheumatol Int. 2008;29:53\u20137.","journal-title":"Rheumatol Int"},{"key":"182_CR14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","volume":"51","author":"M Accorinti","year":"2007","unstructured":"Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Beh\u00e7et\u2019s disease. Jpn J Ophthalmol. 2007;51:191\u20136.","journal-title":"Jpn J Ophthalmol"},{"key":"182_CR15","doi-asserted-by":"crossref","unstructured":"Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-ArfajA. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Beh\u00e7et\u2019s disease. Int Ophthalmol. 2005;26:83\u201392.","DOI":"10.1007\/s10792-006-9006-9"},{"key":"182_CR16","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease: an open-label trial. Arthritis Rheum. 2005;52:2478\u201384.","journal-title":"Arthritis Rheum"},{"key":"182_CR17","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et\u2019s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362\u20138.","journal-title":"J Rheumatol"},{"key":"182_CR18","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(01)06677-6","volume":"358","author":"S Mu\u00f1oz-Fern\u00e1ndez","year":"2001","unstructured":"Mu\u00f1oz-Fern\u00e1ndez S, Hidalgo V, Fern\u00e1ndez-Mel\u00f3n J, Schlincker A, Mart\u00edn-Mola E. Effect of infliximab on threatening panuveitis in Beh\u00e7et\u2019s disease. Lancet. 2001;358:1644.","journal-title":"Lancet"},{"key":"182_CR19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","volume":"358","author":"PP Sfikakis","year":"2001","unstructured":"Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et\u2019s disease. Lancet. 2001;358:295\u20136.","journal-title":"Lancet"},{"key":"182_CR20","first-page":"87","volume":"114","author":"H Tanaka","year":"2010","unstructured":"Tanaka H, Sugita S, Yamada Y, Kawaguchi T, Iwanaga Y, Kamoi K, et al. Effects and safety of infliximab administration in refractory uveoretinitis with Beh\u00e7et\u2019s disease (in Japanese). Nippon Ganka Gakkai Zasshi. 2010;114:87\u201395.","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"182_CR21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/bjo.2009.174888","volume":"95","author":"S Sugita","year":"2011","unstructured":"Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Beh\u00e7et\u2019s disease. Br J Ophthalmol. 2011;95:549\u201352.","journal-title":"Br J Ophthalmol"},{"key":"182_CR22","first-page":"39","volume":"28","author":"T Kaburaki","year":"2010","unstructured":"Kaburaki T, Takamoto M, Numaga J, Kawashima H, Araie M, Ohnogi Y, et al. Genetic association of HLA-A*2601 with ocular Beh\u00e7et\u2019s disease in Japanese patients. Clin Exp Rheumatol. 2010;28:39\u201344. Epub.","journal-title":"Clin Exp Rheumatol"},{"key":"182_CR23","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ophtha.2003.07.018","volume":"111","author":"A Yoshida","year":"2004","unstructured":"Yoshida A, Kawashima H, Motoyama Y, Shibui H, Kaburaki T, Shimizu K, et al. Comparison of patients with Beh\u00e7et\u2019s disease in the 1980s and 1990s. Ophthalmology. 2004;111:810\u20135.","journal-title":"Ophthalmology"},{"key":"182_CR24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00417-009-1234-z","volume":"248","author":"T Kaburaki","year":"2010","unstructured":"Kaburaki T, Araki F, Takamoto M, Okinaga K, Yoshida A, Numaga J, et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10\u00a0years in patients with Beh\u00e7et\u2019s disease. Graefes Arch Clin Exp Ophthalmol. 2010;248:709\u201314.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"182_CR25","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ajo.2004.04.066","volume":"138","author":"NN Markomichelakis","year":"2004","unstructured":"Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoids edema associated with uveitis. Am J Ophthalmol. 2004;138:648\u201350.","journal-title":"Am J Ophthalmol"},{"key":"182_CR26","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/kem261","volume":"46","author":"M Svenson","year":"2007","unstructured":"Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-\u03b1 biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology. 2007;46:1828\u201334.","journal-title":"Rheumatology"},{"key":"182_CR27","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","volume":"54","author":"GJ Wolbink","year":"2006","unstructured":"Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711\u20135.","journal-title":"Arthritis Rheum"},{"key":"182_CR28","doi-asserted-by":"crossref","unstructured":"Baert F, Noman M, Vermeire S, Van Assche G, D\u2019 Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med. 2003;348:601\u20138.","DOI":"10.1056\/NEJMoa020888"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-012-0182-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-012-0182-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-012-0182-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T12:20:36Z","timestamp":1559132436000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-012-0182-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,2]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["182"],"URL":"https:\/\/doi.org\/10.1007\/s10384-012-0182-z","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,2]]}}}